Fresenius

Bad Homburg, Germany Founded: 1912 • Age: 114 yrs
System-critical products and services for healthcare therapies are provided.
Annual revenue $1.6M Latest available
Total funding $50.0M 2 rounds
Employees 37 Tracked headcount
Investors 2 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About Fresenius

Fresenius is a company based in Bad Homburg (Germany) founded in 1912 by Eduard Fresenius. Fresenius has raised $50 million across 2 funding rounds from investors including Elliott Management and DW Management Services. The company has 37 employees as of April 06, 2024. Fresenius has completed 6 acquisitions, including APP Pharma, Eugin and Quirnsalud. Fresenius operates in a competitive market with competitors including Outset Medical, Hemotune, Diality, NxStage and Chongqing Shanwaishan Blood Purification Technology, among others.

  • Headquarter Bad Homburg, Germany
  • Employees 37 as on 06 Apr, 2024
  • Founders Eduard Fresenius
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Fresenius Digital Technology India Private Limited
  • Date of Incorporation 06 Sep, 2021
  • Jurisdiction Bengaluru, Karnataka, India
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $1.59 M (USD)
    220.39
    as on Mar 31, 2023
  • Net Profit
    $156.23 K (USD)
    237.11
    as on Mar 31, 2023
  • EBITDA
    $371.79 K (USD)
    369.6
    as on Mar 31, 2023
  • Total Equity Funding
    $50 M (USD)

    in 2 rounds

  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    37

    as on Apr 06, 2024

  • Investments & Acquisitions
    APP Pharma

    & 5 more

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Fresenius

Headcount 10000+
Employee Profiles 79
Board Members and Advisors 13
Employee Profiles
People
Niklas Schemken
Director Corporate Strategy
People
Thomas Musseleck
Director, Head Of Risk Management Operations
People
Mara Kester
Manager Controlling Esg/sustainability
People
Aslam Khadaroo
Senior Manager Corporate Strategy

Unlock access to complete

Board Members and Advisors
people
Frauke Lehmann
Board Member
people
Iris Löw-Friedrich
Board Member
people
Oscar Romero de Paco
Board Member
people
Wolfgang Kirsch
Chair

Unlock access to complete

Funding Insights of Fresenius

Fresenius has successfully raised a total of $50M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Fresenius

Fresenius has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Elliott Management and DW Management Services.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Locked Locked Locked
Multiple sectors are invested in by the hedge fund.
Locked Locked Locked
Premium access

Investor details for Fresenius

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Fresenius

Fresenius has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include APP Pharma, Eugin and Quirnsalud.

Investments
Premium access

Investment portfolio details for Fresenius

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Multispecialty hospital services are provided through a network.
Locked Locked 2015 Locked
Injectable pharmaceuticals are manufactured and distributed by APP Pharma.
Locked Locked 2002 Locked
Dialysis clinics are operated nationwide in the United States.
Locked Locked 2002 Locked
Premium access

Complete acquisition details for Fresenius

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Fresenius

Premium access

Detailed financials for Fresenius

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Fresenius Comparisons

Fresenius Primary company
Description
System-critical products and services for healthcare therapi...
Location
Bad Homburg, Germany
Founded Year
1912
Annual Revenue
$1.59 M (USD)
Net Profit
$156.23 K (USD)
EBITDA
$371.79 K (USD)
Employees
37
As of 2024
Premium access

Peer comparison for Fresenius

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Fresenius

Fresenius operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Outset Medical, Hemotune, Diality, NxStage and Chongqing Shanwaishan Blood Purification Technology, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Hemodialysis machines with touchscreen displays are provided for medical use.
Locked Locked Locked
Developer of a device for blood purification
Locked Locked Locked
Developer of portable hemodialysis device
Locked Locked Locked
Home and critical care dialysis systems
Locked Locked Locked
Blood purification equipment for kidney failure patients is provided.
Premium access

Detailed competitors of Fresenius

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Fresenius

Premium access

Complete news archive for Fresenius

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Fresenius

Fresenius was founded in 1912 and raised its 1st funding round 96 years after it was founded.

Fresenius is headquartered in Bad Homburg, Germany. It is registered at Bad Homburg, Hesse, Germany.

Stephan Sturm is the current CEO of Fresenius.

Fresenius is a funded company, having raised a total of $50M across 2 funding rounds to date.

As of Apr 06, 2024, the latest employee count at Fresenius is 37.

Annual revenue of Fresenius is $1.59M as on Mar 31, 2023.

Fresenius was established in 1912 in Bad Homburg, Germany, within the healthcare sector. Operations encompass IV drugs and fluids, clinical nutrition, biopharma, transfusion and cell therapies, and infusion systems. Expansion efforts target home dialysis treatments, while digitalization is utilized to enable personalized care. In 2022, annual revenues reached 42.71B, with a net profit of 1.44B recorded. Global reach supports therapy-focused services.

Fresenius's top competitors include Outset Medical, Diality and NxStage.

Fresenius has made 6 acquisitions, including APP Pharma, Eugin, and Quirnsalud.

Fresenius has 2 investors. Key investors include Elliott Management, and DW Management Services.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available